Middletown, NJ, United States of America

Christopher Joseph Sinz

USPTO Granted Patents = 15 (Patent Applications = 4)

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 7.8

ph-index = 5

Forward Citations = 119(Granted Patents)

Location History:

Cranford, NJ (US) (2007 - 2013)
Middletown, NJ (US) (2013 - 2019)
South San Francisco, CA (US) (2018 - 2019)

Company Filing History:

13 out of 2,405

Merck Sharp + Dohme Corp.

Msd R&d (china) Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2007-2019

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10358435 - Triazolyl pyrimidinone compounds as PDE2 inhibitors (2019-07-23),

2. 10287293 - Bicyclic heterocyclic compounds as PDE2 inhibitors (2019-05-14),

3. 10208060 - Inhibitors of HIF prolyl hydroxylase (2019-02-19),

4. 10174037 - Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors (2019-01-08),

5. 10160762 - 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors (2018-12-25),

6. 10000501 - Inhibitors of HIF prolyl hydroxylase (2018-06-19),

7. 9969752 - Inhibitors of HIF prolyl hydroxylase (2018-05-15),

8. 9815796 - Pyrimidone carboxamide compounds as PDE2 inhibitors (2017-11-14),

9. 9708270 - Substituted spiropiperidinyl compounds useful as GPR120 agonists (2017-07-18),

10. 8507512 - Soluble guanylate cyclase activators (2013-08-13),

11. 8455638 - Soluble guanylate cyclase activators (2013-06-04),

12. 7968589 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use (2011-06-28),

13. 7687534 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use (2010-03-30),

14. 7598398 - Acyl indoles, compositions containing such compounds and methods of use (2009-10-06),

15. 7301036 - Cyclic guanidines, compositions containing such compounds and methods of use (2007-11-27),

Title: The Innovative Contributions of Christopher Joseph Sinz

Introduction

Christopher Joseph Sinz is a notable inventor based in Middletown, NJ (US), recognized for his significant contributions to the field of pharmaceutical sciences. With a total of 15 patents to his name, Sinz has focused on developing therapeutic agents aimed at treating various central nervous system disorders. His work has the potential to impact the lives of many individuals suffering from neurological and psychiatric conditions.

Latest Patents

Among his latest patents, Sinz has developed triazolyl pyrimidinone compounds as PDE2 inhibitors. This invention is directed towards pyrimidine carboxamide compounds that serve as therapeutic agents for treating central nervous system disorders associated with phosphodiesterase 2 (PDE2). The compounds are particularly relevant for addressing neurological and psychiatric disorders such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), and Huntington's disease. Another significant patent involves bicyclic heterocyclic compounds as PDE2 inhibitors, which also target similar disorders and offer potential therapeutic benefits.

Career Highlights

Throughout his career, Christopher Joseph Sinz has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Merck & Company, Inc. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of medicine.

Collaborations

Sinz has collaborated with esteemed colleagues such as Emma R Parmee and Ronald M Kim, further enhancing the innovative work being done in his field. These collaborations have played a crucial role in advancing research and developing effective therapeutic solutions.

Conclusion

Christopher Joseph Sinz's contributions to the field of pharmaceutical sciences through his patents and collaborations highlight his commitment to improving treatment options for central nervous system disorders. His innovative work continues to pave the way for advancements in medical therapies.

This text is generated by artificial intelligence and may not be accurate.